Traumatic submacular hemorrhage: available treatment options and synthesis of the literature

Table 1 Clinical data and treatment results in patients with traumatic sub macular hemorrhage

Author	No. of eyes	Treatment	Dose	Baseline BCVA	Final BCVA	Follow-up (months)
Balughatta et al. [22]	3	Intravitreous C3F8	0.3 ml	CF	20/30	3
				CF	20/40
				20/60	20/90
Ohji et al. [55]	5	Intravitreous C3F8	0.4 ml	20/400	20/15	14
			0.4 ml	20/300	20/40	6
			0.5 ml	20/2000	20/200	13
			0.4 ml	20/400	20/50	3
			0.4 ml	20/700	20/200	3
Gopalakrishan et al. [54]	4	Intravitreal C3F8	0.3 ml	CF	20/20	3
				CF	20/63
				20/125	20/125
				CF	20/20
Tsuyama et al. [48]	1	Intravitreous tPA + SF6	12.5 μg/0.05 ml + 0.3 ml	20/70	20/16	4
Araújo et al. [42]	2	Intravitreous tPA + SF6	50 μg/0.05 ml + 0.3 ml	20/63	20/20	4
Araújo et al. [42]	2	Intravitreous tPA + SF6	50 μg/0.05 ml + 0.3 ml	20/200	20/32	4
Hassan et al. [21]	1	Intravitreous tPA + SF6	75 μg/0.15 ml + 0.4 ml	20/200	20/30	9
Holland et al. [49]	2	Intravitreous tPA + SF6 SF6 alone	50 μg + 0.4 ml 0.4 ml	20/125	20/32	12
Holland et al. [49]	2	Intravitreous tPA + SF6 SF6 alone	50 μg + 0.4 ml 0.4 ml	20/100	20/32	12
Kung et al. [41]	1	Intravitreal tPA + C3F8	50 μg + 0.3 ml
Buschini et al. [38]	2	Subretinal tPA	25 μg/0.1 ml	20/100	20/20	3
Buschini et al. [38]	2	Intravitreous tPA + SF6	50 μg + 0.4 ml	20/125	20/63	5
Doi et al. [60]	1	Subretinal tPA	6.9 μg/0.1 ml	HM	20/40	3
Hillenkamp et al. [52]	1	Subretinal tPA + SF6	10–20 μg/0.05–0.1 ml	20/125	20/25	3
Abdul-Salim et al. [81]	1	Intravitreal ranibizumab	0.5 mg	CF	20/63	3

C3F8 perfluoropropane, CF counting fingers, HM hand motion, SF6 sulfurhexafluoride, tPA tissue plasminogen activator

ISSN: 2056-9920